Sugi Predict

Sugi Predict / Compounds / Nornicotine

Nornicotine

Nornicotine

SCHEMBL29362147

c1cncc([C@@H]2CCCN2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRNB2 P17787 9/20 1.00
▸ CHRNA4 P43681 9/20 1.00
▸ CHRNA7 P36544 7/20 1.00
▸ CYP2A6 P11509 4/20 0.90
▸ MEN1 O00255 2/20 0.90
▸ CYP2D6 P10635 2/20 0.90
▸ CYP2C19 P33261 2/20 0.90
▸ KMT2A Q03164 2/20 0.90
▸ POLB P06746 1/20 0.90
▸ SMN1; SMN2 Q16637 1/20 0.90
▸ CYP1A2 P05177 1/20 0.90
▸ CYP2C9 P11712 1/20 0.90
▸ CYP11B2 P19099 1/20 0.55
▸ ALDH1A1 P00352 2/20 0.46
▸ CHRNB4 P30926 2/20 0.46
▸ CHRNA3 P32297 2/20 0.46
▸ CHRNA2 Q15822 2/20 0.46
▸ LMNA P02545 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ HTR3E A5X5Y0 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nornicotine SCHEMBL13090363 1.00 CHRNB2 (1.00) CHRNB2CHRNA4CHRNA7CYP2A6MEN1
Nornicotine SCHEMBL7197292 1.00 CHRNB2 (1.00) CHRNB2CHRNA4CHRNA7CYP2A6MEN1
Nornicotine SCHEMBL29571520 1.00 CHRNB2 (1.00) CHRNB2CHRNA4CHRNA7CYP2A6MEN1
Nornicotine SCHEMBL158145 1.00 CHRNB2 (1.00) CHRNB2CHRNA4CHRNA7CYP2A6MEN1
Nornicotine SCHEMBL158146 1.00 CHRNB2 (1.00) CHRNB2CHRNA4CHRNA7CYP2A6MEN1
Nornicotine SCHEMBL30866559 1.00 CHRNB2 (1.00) CHRNB2CHRNA4CHRNA7CYP2A6MEN1
Nornicotine SCHEMBL932560 0.98 CHRNB2 (0.96) CHRNB2CHRNA4CHRNA7CYP2A6MEN1
Dl-Anabasine SCHEMBL117530 0.95 CHRNB2 (1.00) CHRNB2CHRNA4CHRNA7CYP2A6MEN1
Dl-Anabasine SCHEMBL30835558 0.95 CHRNB2 (1.00) CHRNB2CHRNA4CHRNA7CYP2A6MEN1
Anabasine SCHEMBL29634446 0.95 CHRNB2 (1.00) CHRNB2CHRNA4CHRNA7CYP2A6MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118005607-B Process for the preparation of (S) -nicotine from myosmine 扎诺普瑞玛生命科学有限公司 2025-06-17 — — CN claimed
US-20250163020-A1 Chiral Synthesis of Nornicotine and Nicotine SIEGFRIED AG (CH) 2025-05-22 — — US claimed
CN-119950500-A Tobacco pest-reducing and pain-relieving products and methods thereof 瑞迪美天然有限公司 2025-05-09 — — CN claimed
CN-119908508-A Gasified alkaloid composition and method of use thereof 瑞迪美天然有限公司 2025-05-02 — — CN claimed
EP-4540239-A1 CHIRAL SYNTHESIS OF NORNICOTINE AND NICOTINE Siegfried AG (CH) 2025-04-23 — — EP claimed
CN-119523150-A Gasified alkaloid composition and method of use thereof 瑞迪美天然有限公司 2025-02-28 — — CN claimed
CN-118984653-A Vaporizable alkaloid compositions and methods of use thereof 瑞迪美天然有限公司 2024-11-19 — — CN claimed
CN-117965479-B Imine reductase mutant and application thereof 华南理工大学 2024-08-06 — — CN claimed
CN-116354841-B Method for synthesizing formamide by catalyzing lower amine and carbon dioxide by polymer-based catalyst 中国科学院兰州化学物理研究所 2024-06-14 — — CN claimed
CN-115340524-B Method for preparing (S) -nicotine by methylation of (S) -nornicotine 重庆博腾制药科技股份有限公司 2024-05-28 — — CN claimed
EP-4119671-A1 METHOD FOR SYNTHESIZING (S)-NICOTINE Porton Pharma Solutions Ltd. (CN) 2023-01-18 — — EP claimed
WO-2022268006-A1 IMINE REDUCTASE MUTANT, CO-EXPRESSED ENZYME OF IMINE REDUCTASE AND GLUCOSE DEHYDROGENASE, AND APPLICATION THEREOF 陈泽聪 2022-12-29 — — WO claimed
CN-115491364-A Imine reductase mutant, imine reductase and glucose dehydrogenase coexpression enzyme and application thereof 陈泽聪 2022-12-20 — — CN claimed
CN-115340524-A Method for preparing (S) -nicotine by methylation of (S) -nornicotine 重庆博腾制药科技股份有限公司 2022-11-15 — — CN claimed
WO-2022222913-A1 PREPARATION METHOD FOR L-NICOTINE 黄冈中有生物科技有限公司 2022-10-27 — — WO claimed
CN-113774036-B Imine reductase mutant and application thereof 迪嘉药业集团有限公司 2022-10-11 — — CN claimed
CN-114317472-B High stereoselectivity imine reductase and preparation method and application thereof 长兴制药股份有限公司 2022-07-05 — — CN claimed
US-20220154231-A1 METHODS FOR PREPARING NICOTINE AND INTERMEDIATES THEREOF Shenzhen Hangsen Star Technology Co., Ltd (CN) 2022-05-19 — — US claimed
CN-114317472-A High stereoselectivity imine reductase and preparation method and application thereof 长兴制药股份有限公司 2022-04-12 — — CN claimed
CN-113979993-A Method for asymmetric synthesis of (S) -nicotine 云南萃精生物科技有限责任公司 2022-01-28 — — CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220154231-A1 METHODS FOR PREPARING NICOTINE AND INTERMEDIATES THEREOF IMPDH1, RNGTT, IMPDH2 CHRNB2 717/4885CHRNA4 765/4885CHRNA7 645/4885
US-20250163020-A1 Chiral Synthesis of Nornicotine and Nicotine NNMT, SLC6A12, HNMT CHRNB2 20/4885CHRNA4 24/4885CHRNA7 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.